scholarly article | Q13442814 |
P356 | DOI | 10.1002/ACR.22289 |
P698 | PubMed publication ID | 24470057 |
P50 | author | Adam Platt | Q70920128 |
Morten Asser Karsdal | Q88536436 | ||
Anne C Bay-Jensen | Q91708937 | ||
P2093 | author name string | Claus Christiansen | |
Kim Henriksen | |||
Harry K Genant | |||
Chris Chamberlain | |||
P2860 | cites work | Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 |
ACR/EULAR 2010 rheumatoid arthritis classification criteria | Q26864171 | ||
Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis | Q28943301 | ||
Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats | Q33813357 | ||
Matrix as a modulator of hepatic fibrogenesis | Q34391368 | ||
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis | Q34395462 | ||
Treating rheumatoid arthritis to target: recommendations of an international task force | Q34462557 | ||
Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year | Q35899269 | ||
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients | Q36245889 | ||
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure | Q36672445 | ||
An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression | Q36778521 | ||
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial | Q36974786 | ||
IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis | Q37121710 | ||
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers | Q37350908 | ||
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development | Q37462448 | ||
Serological identification of fast progressors of structural damage with rheumatoid arthritis. | Q37689708 | ||
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs | Q37707612 | ||
Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? | Q37728368 | ||
When is switching warranted among biologic therapies in rheumatoid arthritis? | Q38027571 | ||
Forget personalised medicine and focus on abating disease activity | Q38058492 | ||
Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. | Q38061932 | ||
Immunogenicity and autoimmunity during anti-TNF therapy. | Q38064661 | ||
Evolution of treatment for rheumatoid arthritis | Q38065767 | ||
The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis | Q38088942 | ||
Osteoarthritis--a case for personalized health care? | Q38161654 | ||
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis | Q38502821 | ||
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial | Q43114233 | ||
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes | Q43252247 | ||
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study | Q43300360 | ||
Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab | Q43701379 | ||
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. | Q44431651 | ||
Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. | Q44609355 | ||
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis | Q44616456 | ||
Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis | Q45347170 | ||
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis | Q46068649 | ||
Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis | Q46121066 | ||
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis? | Q47911708 | ||
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial | Q49218023 | ||
Chipping away at the lung cancer genome. | Q54525027 | ||
A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen | Q57279145 | ||
P433 | issue | 9 | |
P921 | main subject | rheumatoid arthritis | Q187255 |
P304 | page(s) | 1273-1280 | |
P577 | publication date | 2014-09-01 | |
P1433 | published in | Arthritis Care and Research | Q15754720 |
P1476 | title | Rheumatoid arthritis: a case for personalized health care? | |
P478 | volume | 66 |
Q52806365 | Age-related collagen turnover of the interstitial matrix and basement membrane: Implications of age- and sex-dependent remodeling of the extracellular matrix. |
Q90102556 | Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders |
Q36481786 | Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study |
Q64091799 | Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept |
Q98564934 | Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis |
Q92146862 | Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies |
Q28551216 | Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study |
Q37694959 | NLRP3 and CARD8 Polymorphisms Influence Higher Disease Activity in Rheumatoid Arthritis |
Q35971518 | Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis |
Q38675211 | Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers |
Q91973492 | The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases |
Q64229636 | Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis |
Q53820042 | Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. |
Search more.